Amoy Diagnostics Co., Ltd.

XSEC:300685 Stock Report

Market Cap: CN¥9.8b

Amoy Diagnostics Valuation

Is 300685 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300685 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300685 (CN¥24.8) is trading above our estimate of fair value (CN¥23.89)

Significantly Below Fair Value: 300685 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300685?

Key metric: As 300685 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300685. This is calculated by dividing 300685's market cap by their current earnings.
What is 300685's PE Ratio?
PE Ratio31x
EarningsCN¥315.02m
Market CapCN¥9.77b

Price to Earnings Ratio vs Peers

How does 300685's PE Ratio compare to its peers?

The above table shows the PE ratio for 300685 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.4x
600645 Vcanbio Cell & Gene Engineering
83.2x23.0%CN¥8.9b
300406 Beijing Strong BiotechnologiesInc
15.5x23.2%CN¥8.2b
688276 Changchun BCHT Biotechnology
25.7x40.7%CN¥10.7b
300841 Chengdu Kanghua Biological Products
13.1x18.0%CN¥7.1b
300685 Amoy Diagnostics
31x19.6%CN¥9.8b

Price-To-Earnings vs Peers: 300685 is good value based on its Price-To-Earnings Ratio (31x) compared to the peer average (34.4x).

Price to Earnings Ratio vs Industry

How does 300685's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300685 31.0xIndustry Avg. 35.5xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300685 is good value based on its Price-To-Earnings Ratio (31x) compared to the CN Biotechs industry average (35.5x).

Price to Earnings Ratio vs Fair Ratio

What is 300685's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300685 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31x
Fair PE Ratio26x

Price-To-Earnings vs Fair Ratio: 300685 is expensive based on its Price-To-Earnings Ratio (31x) compared to the estimated Fair Price-To-Earnings Ratio (26x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300685 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥24.80
CN¥29.92
+20.6%
12.3%CN¥36.00CN¥23.84n/a6
Nov ’25CN¥24.33
CN¥29.92
+23.0%
12.3%CN¥36.00CN¥23.84n/a6
Oct ’25CN¥24.00
CN¥27.01
+12.5%
16.8%CN¥36.00CN¥23.00n/a6
Sep ’25CN¥18.85
CN¥27.01
+43.3%
16.8%CN¥36.00CN¥23.00n/a6
Aug ’25CN¥18.68
CN¥27.90
+49.3%
16.1%CN¥36.00CN¥23.80n/a6
Jul ’25CN¥18.29
CN¥28.60
+56.4%
14.4%CN¥36.00CN¥23.84n/a6
Jun ’25CN¥18.40
CN¥28.60
+55.4%
14.4%CN¥36.00CN¥23.84n/a6
May ’25CN¥21.88
CN¥28.60
+30.7%
14.4%CN¥36.00CN¥23.84n/a6
Apr ’25CN¥22.81
CN¥29.50
+29.3%
16.5%CN¥39.00CN¥26.00n/a5
Mar ’25CN¥22.50
CN¥29.52
+31.2%
14.0%CN¥39.00CN¥26.00n/a7
Feb ’25CN¥17.20
CN¥31.94
+85.7%
16.7%CN¥42.00CN¥26.00n/a8
Jan ’25CN¥21.98
CN¥31.94
+45.3%
16.7%CN¥42.00CN¥26.00n/a8
Dec ’24CN¥22.36
CN¥31.94
+42.8%
16.7%CN¥42.00CN¥26.00n/a8
Nov ’24CN¥21.35
CN¥32.53
+52.4%
15.5%CN¥42.00CN¥26.00CN¥24.338
Oct ’24CN¥24.85
CN¥33.47
+34.7%
15.4%CN¥42.00CN¥28.00CN¥24.008
Sep ’24CN¥24.05
CN¥33.47
+39.2%
15.4%CN¥42.00CN¥28.00CN¥18.858
Aug ’24CN¥25.46
CN¥35.97
+41.3%
17.2%CN¥46.00CN¥28.00CN¥18.686
Jul ’24CN¥24.26
CN¥38.58
+59.0%
13.6%CN¥46.00CN¥32.83CN¥18.294
Jun ’24CN¥26.37
CN¥38.58
+46.3%
13.6%CN¥46.00CN¥32.83CN¥18.404
May ’24CN¥28.14
CN¥38.58
+37.1%
13.6%CN¥46.00CN¥32.83CN¥21.884
Apr ’24CN¥28.14
CN¥37.03
+31.6%
17.1%CN¥46.00CN¥28.65CN¥22.814
Mar ’24CN¥29.64
CN¥35.47
+19.7%
18.3%CN¥46.00CN¥28.65CN¥22.505
Feb ’24CN¥29.12
CN¥35.47
+21.8%
18.3%CN¥46.00CN¥28.65CN¥17.205
Jan ’24CN¥26.45
CN¥38.27
+44.7%
25.2%CN¥53.00CN¥28.65CN¥21.985
Dec ’23CN¥26.87
CN¥39.87
+48.4%
30.8%CN¥61.00CN¥28.65CN¥22.365
Nov ’23CN¥24.13
CN¥39.87
+65.2%
30.8%CN¥61.00CN¥28.65CN¥21.355

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

7D

-2.6%

1Y

13.6%